Showing results (181-190 of 427) with videos related to

Sort By:
Pageof 43
Journal of Clinical Medicine|January 11, 2024
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid LeukemiaAlessandro Costa, Elisabetta Abruzzese, Roberto Latagliata, et al.
Annals of Hematology|May 29, 2020
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patientsEmilia Scalzulli, Gioia Colafigli, Roberto Latagliata, et al.
Blood Reviews|April 12, 2025
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapyRaffaele Palmieri, Anna Candoni, Francesco Di Raimondo, et al.
Hematological Oncology|May 8, 2015
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?Federico Vozella, Roberto Latagliata, Ida Carmosino, et al.
Annals of Hematology|June 11, 2014
Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cellsMassimo Breccia, Maria Stefania De Propris, Caterina Stefanizzi, et al.
Annals of Hematology|May 13, 2019
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real lifeMatteo Molica, Gioia Colafigli, Emilia Scalzulli, et al.
Acta Haematologica|December 1, 2006
Late relapses in acute promyelocytic leukaemiaRoberto Latagliata, Ida Carmosino, Massimo Breccia, et al.
Journal of Clinical Medicine|November 9, 2024
Does Occupational Exposure to Chemicals/Carcinogens Affect the Hematological Parameters of Workers?Giuseppe La Torre, Maria Vittoria Manai, Luca Moretti, et al.
Haematologica|February 3, 2004
Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapyMassimo Breccia, Daniela Diverio, Nélida Inés Noguera, et al.
European Journal of Haematology|January 23, 2013
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemiaMaria Teresa Voso, Massimo Breccia, Monia Lunghi, et al.
Pageof 43